Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.41 +1.46 (+2.87%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO
Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 sales. 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These big pharma stocks arguably aren't receiving the respect they deserve. 
Via The Motley Fool
Topics Intellectual Property
2 Healthcare Stocks That Are Losing to the S&P 500 This Year
Wall Street might be underestimating these companies' potential. 
Via The Motley Fool
Topics Stocks
Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China
More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the American market. 
Via Benzinga
Topics Law Enforcement Supply Chain
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, contributory, and induced infringement claims. 
Via Benzinga
Topics Intellectual Property
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Meets Caviar Cruise Standards for Quality Investing
The Caviar Cruise stock screener identifies top long-term investments like Novo Nordisk (NVO), with strong revenue growth, high ROIC, solid cash flow, and pricing power—ideal for quality investors. 
Via Chartmill
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 5 Years
 
Via Benzinga
Americans Are Turning To DIY Weight Loss Injections to Dodge $1,000+ Monthly Drug Costs
 
Via Benzinga
2 Beaten-Down Dividend Growth Stocks to Buy on the Dip
Via The Motley Fool
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Via The Motley Fool
Topics Intellectual Property
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A potential undervalued opportunity in healthcare
NOVO-NORDISK (NYSE:NVO) appears undervalued with strong profitability, solid growth, and a reasonable valuation, making it a potential candidate for value investors in the healthcare sector. 
Via Chartmill
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Via The Motley Fool
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note. 
Via The Motley Fool
Topics Intellectual Property
Ozempic, Mounjaro Users Cut $6.5 Billion From Grocery Bills: GLP-1 Boom Triggers Panic In Packaged Food Aisles
GLP-1 medications are delivering a $6.5 billion blow to U.S. grocery spending, with weight-loss drugs altering consumer purchasing patterns. 
Via Benzinga
Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder
Via The Motley Fool
Topics Intellectual Property
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock at a Reasonable Valuation
NOVO-NORDISK (NYSE:NVO) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks in the pharmaceutical sector. 
Via Chartmill
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Absurdly Cheap Growth Stocks to Load Up On Right Now
Via The Motley Fool
Topics World Trade
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes
An update on Sana Biotechnology. 
Via Benzinga
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing'
Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate. 
Via Benzinga
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
Via The Motley Fool
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady. 
Via Benzinga
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%. 
Via Stocktwits
Topics ETFs Government Stocks
Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe
In addition to the submission to the EMA, Novo Nordisk aims to make the higher dose of Wegovy widely available throughout the European Union. 
Via Stocktwits
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.